About - KVUE :

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.

Employees - 22000, CEO - Thibaut Mongon, Sector - Consumer Defensive, Country - US, Market Cap -

Altman ZScore(max is 10): 2.29, Piotroski Score(max is 10): 5, Working Capital: $-134000000, Total Assets: $27132000000, Retained Earnings: $-136000000, EBIT: 2427000000, Total Liabilities: $16402000000, Revenue: $15141000000

AryaFin Target Price - $23.03 - Current Price $ - Analyst Target Price $

Stats & Key Metrics
TickerKVUE
Index
Curent Price
Change
Market Cap
Average Volume
Income
Sales
Book Value/Share
Cash/Share
Dividend Est
Dividend TTM
Dividend Ex-Date
Employees
Moving Avg 20days
Moving Avg 50days
Moving Avg 200days
Shares Outstanding
Earnings Date
Inst. Ownership
Key Ratios & Margins
Price/Earnings
Forwad P/E
PE Growth
Price/Sales
Price/Book
Price/Cash
Price/FCF
Quick Ratio
Current Ratio
Debt/Equity
Return on Assets
Return on Equity
Return on Investment
Gross Margin
Ops Margin
Profit Margin
RSI
BETA(β)
From 52week Low
From 52week High
Earnings & Valuation
EPS
EPS next Year
EPS next Qtr
EPS this Year
EPS next 5 Year
EPS past 5 Year
Sales past 5 Year
EPS Y/Y
Sales Y/Y
EPS Q/Q
Sales Q/Q
Sales Surprise
EPS Surprise
ATR(14)
Perf Week
Perf Month
Perf Quarter
Perf Year
Perf YTD
Target Price

AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer